Evercore Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $75
Evercore analyst Liisa Bayko maintains $Insmed(INSM.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success rate of 45.1% and a total
Insmed Incorporated (INSM) Surged Following Positive Data For Its Drug
Barclays Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $90
Barclays analyst Leon Wang maintains $Insmed(INSM.US)$ with a buy rating, and maintains the target price at $90.According to TipRanks data, the analyst has a success rate of 71.4% and a total
Barclays Sticks to Their Buy Rating for Insmed (INSM)
Insmed(INSM.US) Officer Sells US$10.61 Million in Common Stock
$Insmed(INSM.US)$ Officer Flammer Martina M.D. sold 149K shares of common stock on Sep 6, 2024 at an average price of $71.23 for a total value of $10.61 million.Source: Announcement What is
Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today
Stifel Maintains Insmed(INSM.US) With Buy Rating
Stifel analyst Stephen Willey maintains $Insmed(INSM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 41.4% and a total average return of 7.0% over the past year.
Insmed Maintains Competitive Edge Amid Lackluster Trial Results for Rival Drug BI 1291583
Cantor Fitzgerald Reiterates Overweight on Insmed
Insmed Incorporated (INSM): Hedge Funds Are Recommending This Biotech Stock Now
Form 144 | Insmed(INSM.US) Officer Proposes to Sell 17.36 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 6, $Insmed(INSM.US)$ Officer Flammer Martina M.D. intends to sell 243.92K shares of its common stock on Sep 6, with a total market value of approximately $17.36 million.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated's (NASDAQ:INSM) Business Is Trailing The Industry But Its Shares Aren't
Express News | Insmed Inc : Goldman Sachs Adds Stock to Its US Conviction List
H.C. Wainwright Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $90
H.C. Wainwright analyst Andrew Fein maintains $Insmed(INSM.US)$ with a buy rating, and maintains the target price at $90.According to TipRanks data, the analyst has a success rate of 50.9% and a
Insmed's Brensocatib Poised for Market Leadership: A Buy Rating Amidst Unthreatening Competition
Insmed (INSM) Rose Due to Positive Trial Results
Insmed Stock Surges 168% in the Past Six Months: Here's Why
$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
Watching Shares Of Insmed; Traders Circulating Mentions Of Company In Popular M&A Blog